Free Newsletter
Drug debate enters U.K. election
Drug finance is becoming an election issue in the U.K. this year. The Liberal Democrats are backing a plan that would change National Health Service rules to allow patients to pay for drugs that the government won't finance. Now, the rules say patients who choose to foot the bill for expensive meds also have to pay for the rest of their treatment, too.
As you know, there's been increasingly heated debate in the U.K. as the National Institute for Clinical Excellence has rejected one costly cancer treatment after another. The drugs aren't cost-effective, the rationing agency has said. An outcry from patients and their advocates ensued.
Allowing patients to pay for their own expensive meds might be an effective work-around for those who can afford it. But patients who can't come up with thousands of dollars for their meds would be out of luck. And experts say the NHS would melt down if it had to spend the $100 billion-plus necessary for those rejected drugs.
- read the story in The Times
- see The Mail's article
Related Articles:
Novartis: UK may lose new drugs
Investor says biotech is languishing in the UK
UK blueprints $400M biotech lab of the future
UK biotechs feeling the chill from investors
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: